[go: up one dir, main page]

Shrivastava et al., 2023 - Google Patents

COVID-19: Molecular Pathogenesis and Prospective Therapeutic Interventions

Shrivastava et al., 2023

Document ID
3455366118586292061
Author
Shrivastava P
Vyas S
Publication year
Publication venue
Viral Drug Delivery Systems: Advances in Treatment of Infectious Diseases

External Links

Snippet

COVID-19 is a catastrophe taking a massive toll on humanity across the world. It is a highly transmissible airborne infection. The pathogen responsible for causing COVID-19 is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronaviruses (CoV) are named …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Triggle et al. A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic
Florindo et al. Immune-mediated approaches against COVID-19
Saha et al. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19
Alipoor et al. COVID-19: molecular and cellular response
Sohag et al. Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
Das et al. An overview of key potential therapeutic strategies for combat in the COVID-19 battle
Lopez-Cantu et al. From bench to the clinic: the path to translation of nanotechnology-enabled mRNA SARS-CoV-2 vaccines
Chauhan et al. Interpretative immune targets and contemporary position for vaccine development against SARS‐CoV‐2: a systematic review
Saini COVID-19 pandemic: potential phase III vaccines in development
Harne et al. SARS-CoV-2 infection and immune responses
van de Ven et al. Systemic and respiratory T-cells induced by seasonal H1N1 influenza protect against pandemic H2N2 in ferrets
Bayat et al. Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms
Marei et al. Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches
Ullah et al. A review of the progress of COVID-19 vaccine development
Pal et al. Current updates on adaptive immune response by B cell and T cell stimulation and therapeutic strategies for novel coronavirus disease 2019 (COVID-19) treatment
Zandi et al. A snapshot of different types of under research vaccines against COVID-19: a review
Shrivastava et al. COVID-19: Molecular Pathogenesis and Prospective Therapeutic Interventions
Hirahata et al. A review of SARS-CoV-2 virology, vaccines, variants and their impact on the COVID-19 pandemic
Singh et al. Immunological response of the respiratory tract in the SARS-CoV-2 infection
Aggarwal et al. In quest of a COVID-19 vaccine: a race against time
Chatterjee et al. A review on the SARS-CoV-2 mediated global pandemic: proximal origin, pathogenicity and therapeutic approaches
Hudakova et al. Fundamental and advanced therapies, vaccine development against SARS-CoV-2
Mishra et al. History, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
Chukwuemeka et al. SARS-CoV-2 recombinant spike protein-based vaccine: A promising candidate against the recent imperial coronavirus disease (COVID-19)
Singh et al. COVID‐19 vaccination: A clinical perspective